4.7 Review

Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer

期刊

EUROPEAN JOURNAL OF CANCER
卷 106, 期 -, 页码 144-159

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2018.11.002

关键词

NSCLC; Immunotherapy; Predictive biomarkers; Lung cancer; PD-L1; Tumour mutational burden; Tumour microenvironment; Microsatellite instability

类别

向作者/读者索取更多资源

Immune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed. (C) 2018 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据